4D Molecular Therapeutics (FDMT) Equity Average (2021 - 2025)
Historic Equity Average for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $394.9 million.
- 4D Molecular Therapeutics' Equity Average fell 3079.11% to $394.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.9 million, marking a year-over-year decrease of 3079.11%. This contributed to the annual value of $409.2 million for FY2024, which is 5179.65% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Equity Average stood at $394.9 million, which was down 3079.11% from $445.3 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Equity Average registered a high of $594.5 million during Q2 2024, and its lowest value of $225.0 million during Q1 2023.
- Over the past 5 years, 4D Molecular Therapeutics' median Equity Average value was $307.6 million (recorded in 2022), while the average stood at $353.4 million.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Equity Average soared by 11864.85% in 2024, and later tumbled by 3079.11% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Equity Average stood at $271.6 million in 2021, then fell by 11.13% to $241.4 million in 2022, then soared by 32.1% to $318.9 million in 2023, then soared by 66.76% to $531.8 million in 2024, then fell by 25.73% to $394.9 million in 2025.
- Its last three reported values are $394.9 million in Q3 2025, $445.3 million for Q2 2025, and $490.2 million during Q1 2025.